Skip to content

BIO: CMS decision enormous setback for Alzheimer’s patients, dangerous infringement on FDA autonomy

BIO: CMS decision enormous setback for Alzheimer’s patients, dangerous infringement on FDA autonomy On April 7, the Centers for Medicare and Medicaid Services held to its original decision to limit coverage of the Biogen’s Alzheimer’s disease treatment Aduhelm — along with other drugs like it — to clinical trials. Michelle McMurry-Heath, M.D., Ph.D., president and…

Read More

Biotech joins efforts to aid in humanitarian relief in Ukraine

Biotech joins efforts to aid in humanitarian relief in Ukraine The biotech and life sciences industry is coming together to donate a range of critical medical supplies, equipment, and medications to the people of Ukraine. “The conflict in Ukraine and violence from Russia defies international law, norms and modern sensibilities,” said BIO President and CEO…

Read More

CMS decision not to cover Alzheimer’s treatment a bad one

CMS decision not to cover Alzheimer’s treatment a bad one NCBIO stands in solidarity with patient advocates and industry leaders in opposing the Centers for Medicare and Medicaid Services’ draft proposal to restrict coverage for current and future Alzheimer’s drugs targeting beta amyloid, a known hallmark of the disease.  Restricting coverage is a bad idea…

Read More

Laura Gunter: Biotech policies should protect patients, innovation

Laura Gunter: Biotech policies should protect patients, innovation The ongoing response to the COVID-19 pandemic has highlighted the critical role of the North Carolina life sciences industry in battling our most serious public health threats. When faced with the threat of COVID-19, biotechnology companies — many based right here in North Carolina — answered the…

Read More

Pharmaceutical Prescribing Labels: An Enormous Opportunity to Eliminate Pointless Paper Waste in the United States

Pharmaceutical Prescribing Labels: An Enormous Opportunity to Eliminate Pointless Paper Waste in the United States This post originally appeared on the website of the Environmental Paper Network. A serious approach to addressing climate change must include the proactive elimination of unnecessary paper consumption. Paper is an important and useful material that should be produced and…

Read More

BIO: Build Back Better Act weakens U.S. innovation ecosystem, hurts patients

BIO: Build Back Better Act weakens U.S. innovation ecosystem, hurts patients Michelle McMurry-Heath, M.D., Ph.D., president and CEO of the Biotechnology Innovation Organization, released the following statement after the House of Representatives passed the Build Back Better Act on Nov. 19: “The legislation that passed the House today will upend a successful Medicare system and…

Read More

BIO: What happened with the Orphan Drug Tax Credit

BIO: What happened with the Orphan Drug Tax Credit During a busy week in Congress, Democrats included a change to the Orphan Drug Tax Credit that would negatively impact research on rare diseases affecting millions of Americans. The U.S. House of Representatives has several committees marking up the Senate’s $3.5 trillion budget reconciliation package. (Here’s…

Read More